Lataa...
TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III
BACKGROUND: Transmembrane protein 106B (TMEM106B) has been identified as a risk factor for frontotemporal lobar degeneration, which is the second most common form of progressive dementia in people under 65 years of age. Mutations in charged multivesicular body protein 2B (CHMP2B), which is involved...
Tallennettuna:
| Julkaisussa: | Mol Brain |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4676093/ https://ncbi.nlm.nih.gov/pubmed/26651479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13041-015-0177-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|